ストックスクリーナーアプリを入手
5.05
1.41%
0.07
アフターアワーズ：
5.05
前日終値:
$4.98
開ける：
$5.01
24時間の取引高:
722.60K
Relative Volume:
0.82
時価総額：
$305.34M
収益：
$217.78M
当期純損益:
$-239.55M
株価収益率:
-1.2472
EPS:
-4.0492
ネットキャッシュフロー:
$-127.30M
1週間 パフォーマンス:
-1.56%
1か月 パフォーマンス:
-7.17%
6か月 パフォーマンス:
-30.34%
1年 パフォーマンス:
+4.55%
1日の値動き範囲:
$4.93
$5.07
1週間の範囲:
$4.93
$5.33
52週間の値動き範囲:
$4.27
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.05 | 305.34M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-05 | 開始されました | Truist | Buy |
| 2025-11-05 | 開始されました | B. Riley Securities | Buy |
| 2024-10-31 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
| 2021-05-12 | 開始されました | BofA Securities | Buy |
| 2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
| 2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
| 2019-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 繰り返されました | Jefferies | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-09-21 | 再開されました | Oppenheimer | Outperform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-06-27 | 再開されました | Piper Jaffray | Overweight |
| 2017-05-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Oppenheimer | Outperform |
| 2016-11-09 | 開始されました | Aegis Capital | Buy |
| 2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds - Law360
Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug - Bloomberg Law News
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA Initiates Coverage On Oppenheimer -- Rating Outperform with $10.00 Price Target - GuruFocus
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com
Vanda Pharmaceuticals stock slips as 2025 loss widens - AD HOC NEWS
Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens By Investing.com - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead - TradingView
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth - TradingView
Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus key phase III trials, set the stage for major revenue growth - TradingView
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Pharmaceuticals Inc. (VNDA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug - BioBuzz
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences - StreetInsider
Vanda Pharmaceuticals Inc. (VNDA) Peer Comparison – Compare with Others - valueresearchonline.com
Convert Vanda Pharmaceuticals Inc. (VNDA) to Canadian Dollar (CAD) - Crypto.com
Vanda Pharmaceuticals Mallorca Women's Championships 2026 Scores | Latest Scores & Live Updates – WTA Official - WTA Tennis
Millennium Management Expands Vanda Pharmaceuticals Stake Amid D - GuruFocus
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - Sahm
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA) - Stock Titan
DC Circuit Partially Rejects Vanda’s Fight of Generic Sleep Drug - Bloomberg Law News
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Inc (VM4.DU) insider ownership and holdings - Yahoo Finance Australia
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):